Revenue: As of FY2025 Q1, the actual value is USD 3.17 M.EPS: As of FY2025 Q1, the actual value is USD -0.37.<h3>Healthcare Segment</h3><ul><li>Net Revenues: $3,161,431 for the three months ended March 31, 2025, compared to $0 for the same period in 2024, due to the acquisition of Myrtle and RCHI.</li><li>Operating Expenses: $4,010,379 for the three months ended March 31, 2025, compared to $0 for the same period in 2024.</li><li>Segment Loss: $844,598 for the three months ended March 31, 2025.</li></ul><h3>Labs and Life Segment</h3><ul><li>Net Revenues: $8,489 for the three months ended March 31, 2025, compared to $7,180 for the same period in 2024.</li><li>Operating Expenses: $31,494 for the three months ended March 31, 2025, compared to $166,630 for the same period in 2024.</li><li>Segment Loss: $23,005 for the three months ended March 31, 2025, compared to $159,450 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $1,337,591 for the three months ended March 31, 2025, compared to $406,302 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $1,286,230 for the three months ended March 31, 2025, compared to $370,720 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Healthcare Segment: The company plans to expand the Myrtle business model by acquiring additional operating facilities and replicating the model in other rural hospital properties or suitable premises.</li><li>Labs and Life Segment: The company is focusing on its Bioinformatics Services offering and research and development in health and wellness testing powered by machine learning and artificial intelligence.</li></ul><h3>Strategic Initiatives</h3><ul><li>Reverse Stock Split: Implemented a 1-for-10 reverse stock split effective April 28, 2025.</li><li>Amended and Restated Strata Purchase Agreement: Extended the maturity date to June 30, 2026, and improved the purchase price definition.</li></ul><h3>Risks and Challenges</h3><ul><li>The company faces substantial doubt about its ability to continue as a going concern due to insufficient capital to fund operations for at least 12 months.</li></ul>

FOXO TECHNOLOGIES INC | 10-Q: FY2025 Q1 Revenue: USD 3.17 M